Optimal multidisciplinary treatment of oral cavity mucosal melanoma: outcome analysis in a case series
| Autor: | Eugenio Maiorano, Salvatore Pisconti, Mario Giuliano, Manuel Conson, Francesco Perri, Giuseppina Della Vittoria Scarpati, Matteo Favia, Francesco Longo, Bonamonte Domenico, Franco Ionna, Gianfranco Favia |
|---|---|
| Přispěvatelé: | Perri, Francesco, Pisconti, Salvatore, Favia, Matteo, Scarpati, Giuseppina Della Vittoria, Conson, Manuel, Giuliano, Mario, Ionna, Franco, Longo, Francesco, Domenico, Bonamonte, Maiorano, Eugenio, Favia, Gianfranco |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Cancer Research medicine.medical_treatment Outcome analysis Disease-Free Survival oral cavity mucosal melanoma 03 medical and health sciences 0302 clinical medicine Internal medicine Adjuvant therapy Biomarkers Tumor Medicine CD21 Humans CD20 Pharmacology (medical) 030212 general & internal medicine Melanoma Aged Pharmacology Chemotherapy Adjuvant radiotherapy biology business.industry Mouth Mucosa adjuvant therapy Immunotherapy Middle Aged CD3 Mouth Neoplasm Immunohistochemistry Oral Cavity Mucosal Melanoma 030220 oncology & carcinogenesis biology.protein CD31 Female Mouth Neoplasms Radiotherapy Adjuvant immunotherapy business Adjuvant Human |
| Zdroj: | Anti-cancer drugs. 28(3) |
| ISSN: | 1473-5741 |
| Popis: | Oral cavity mucosal melanomas (OCMM) represent only 3% of all malignant melanomas. Surgery is the mainstay of treatments and it is often followed by adjuvant radiotherapy. The role of adjuvant immunotherapy and/or chemotherapy is still debated and to date neither treatment is routinely used. From January 1990 to January 2010, we have collected from our database data of 20 patients with a histologically proven diagnosis of OCMM. Upfront surgery, followed by adjuvant radiotherapy was performed in 16/20 (80%) patients. Immunohistochemical analysis was carried out on all tissue samples and the following markers were assessed: Ki-67, HMG-45, Melan-A, S-100, CD31, CD35, CD20, CD21, and CD3. Although Ki-67, HMG-45, Melan-A, and S-100 were assessed in tumor cells, the analysis of CD31, CD21, CD20, CD3, and CD35 was carried out on the tumor-infiltrating lymphocytes. Patient outcome was analyzed and associated with clinical and Immunohistochemical tumor characteristics. The median overall survival (OS) was 12 months, with a 2-year OS rate of 30%. The median progression-free survival (PFS) was 9 months, with a 2-year PFS rate of 25%. Grade of lymphocyte infiltration (CD20 and CD3 expression) correlated strongly with prognosis. Interestingly, overexpression of CD21 along with downregulation of CD31 was significantly associated with better OS and PFS, whereas the reversal features correlated with a poor prognosis. Our report shows that patients affected by OCMM have a poor prognosis despite the administration of multimodal treatments. Moreover, our analysis suggests that the evaluation of several biomarkers, especially in tumor-infiltrating lymphocytes, may identify categories of patients with distinct immune response against the tumor and possibly different treatment response and prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|